Psychotropic drug–related weight gain (PDWG) is a common occurrence and is highly
associated with non-initiation, discontinuation, and dissatisfaction with psychiatric drugs …

Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common
chronic liver disease worldwide and can progress to serious complications, including …

Introduction Reports of suicidality associated with glucagon-like peptide 1 receptor agonists
(GLP-1 RAs) have been reported to the European Medicines Agency (EMA) and the United …

Background Reduced brain volume, impaired cognition, and possibly a range of
psychoneurological disorders have been reported in patients with non-alcoholic fatty liver …

The novel term metabolic dysfunction-associated fatty liver disease (MAFLD), which has
been proposed to describe the major cause of hepatic disease, pinpoints the coexistence of …

Background The relationship between depressive symptoms and chronic liver disease
(CLD) is still unclear. We aimed to determine whether depressive symptoms are associated …

Abstract Background Persons with Major Depressive Disorder (MDD), notably treatment-
resistant depression (TRD), are differentially affected by type 2 diabetes mellitus and …

Baek et al in this issue of the Journal present results from a longitudinal observational study
that aimed to ascertain whether a correlation exists between depressive symptom …

Undertreated medical illnesses can compound the disabling cognitive deficits of
schizophrenia. Obstructive sleep apnea (OSA) impairs cognitive domains also affected by …

Within the last year, the European Medicines Agency (EMA), Food and Drug Administration
(FDA) and the Medicines and Healthcare Products Regulatory Agency in the United …